| Literature DB >> 35265752 |
H Onohuean1,2,3, E Agwu4,5, U U Nwodo2,3.
Abstract
Adequate comprehension of the genomics of microbial resistance to an antimicrobial agent will advance knowledge on the management of associated pathologies and public health safety. However, continued emergences and reemergence of pathogens, including Vibrio species, hallmarks a potential knowledge gap. A clear understanding of the process and forecast of the next trend should be in place to nip in the bud, microbial acquisition of resistance to antibiotics. Therefore, this two-decade (1 January 2000 to 31 December 2019) systematic review and meta-analytical study articulated the prevalence and incidence of antibiotics resistance genes in Vibrio species isolated from environmental samples. Articles from the Web of Science and PubMed electronic databases was engaged. Heterogeneity of the data and bias were analyzed with random effect model meta-analysis and funnel plot. A total of 1920 Vibrio sp. were reported by the ten selected articles included in this study; out of which 32.39% of identified isolates displayed antimicrobial resistance and associated genes. The distribution of antibiotics resistance genes in Vibrio sp., reported within six countries was 21% tetracycline (tet), and 20% sulphonamide (sul) and β-lactamase (bla) respectively. The quinolone, tetracycline and sulfonamide resistance genes showed 32.97% (95% CI 0.18-0.53) prevalence while chloramphenicol, macrolides and aminoglycoside resistance genes are expressed in percentages as 28.67% (95% CI 0.15-0.47) and β-lactamase resistance genes 27.93% (95% CI 0.11-0.56) respectively. The Vibrio antibiotics resistance genes (V-ARG) distribution depicts no regular trend or pattern from the analyzed data. Consequently, more studies would be required to articulate the structure of cohesion in the distribution of the resistance determinants in microbes.Entities:
Keywords: Antibiotics resistance genes; Environmental; Incidents; Isolates; Prevalence; Vibrio species
Year: 2022 PMID: 35265752 PMCID: PMC8899705 DOI: 10.1016/j.heliyon.2022.e08845
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Figure 1Study selection flowchart.
Descriptive summary of qualified studies (n = 10).
| s/n | Authors and PY | antibiotics | ARG | ts | ps | %P | Country | SS | study period | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Not mention | 31 | 9 | 29.03 | Iran | Prawn | Feb–Aug 2015 | |||
| 31 | 7 | 22.58 | ||||||||
| 31 | 10 | 32.26 | ||||||||
| 31 | 4 | 12.90 | ||||||||
| 2 | cephalosporin | 5 | 2 | 40.00 | China | Foods | June 2014–Aug 2015 | |||
| cephalosporin | 5 | 1 | 20.00 | |||||||
| cephalosporin | 5 | 2 | 40.00 | |||||||
| 3 | quinolone | 39 | 18 | 46.15 | China | Foods | 2015–2016 | |||
| quinolone | 39 | 10 | 25.64 | |||||||
| quinolone | 39 | 5 | 12.82 | |||||||
| quinolone | 39 | 2 | 5.13 | |||||||
| quinolone | 39 | 1 | 2.56 | |||||||
| 4 | streptomycin | 50 | 3 | 6.00 | Haiti | Water | Jul-12 | |||
| streptomycin | 50 | 11 | 22.00 | |||||||
| sulfonamide | 50 | 41 | 82.00 | |||||||
| sulfonamide | 50 | 3 | 6.00 | |||||||
| erythromycin | 50 | 45 | 90.00 | |||||||
| erythromycin | 50 | 1 | 2.00 | |||||||
| 5 | β-lactamase | 19 | 19 | 100.00 | Brazil | oysters & mussels | Feb 89 – Jan 90 | |||
| 6 | penicillins, cephalosporin & carbapenem | 3 | 3 | 100.00 | Southern Vietnam | Environmental | 2010–2013 | |||
| 7 | chloramphenicol | 8 | 8 | 100.00 | Malaysia | shrimp | Jan 2014–June 2014 | |||
| kanamycin | 52 | 15 | 28.85 | |||||||
| 8 | tetracycline | 54 | 46 | 85.19 | Eastern Austria | Lake | May' 11- Oct '12 | |||
| beta-lactam, Ampicillin | 54 | 7 | 12.96 | |||||||
| Beta-lactam | 54 | 2 | 3.70 | |||||||
| Phenicol | 54 | 3 | 5.56 | |||||||
| sulfonamide and bicyclomycin | 54 | 46 | 85.19 | |||||||
| MATE | 54 | 19 | 35.19 | |||||||
| 9 | tetracycline | 58 | 45 | 77.59 | India | Fish, oyster, clam, olluscs | 2011–2014 | |||
| co-trimoxazole | 38 | 12 | 31.58 | |||||||
| ampicillin | 125 | 8 | 6.40 | |||||||
| cefotaxime | 62 | 5 | 8.06 | |||||||
| chloramphenicol | 15 | 5 | 33.33 | |||||||
| nalidixic acid | 71 | 9 | 12.68 | |||||||
| 10 | Not mention | 73 | 12 | 16.44 | Malaysia | Seawater & fish | ||||
| 73 | 39 | 53.42 | ||||||||
| 73 | 15 | 20.55 | ||||||||
| 73 | 16 | 21.92 | ||||||||
| 73 | 14 | 19.18 | ||||||||
| 73 | 59 | 80.82 | ||||||||
| 73 | 40 | 54.79 |
PY = Publication years, ARG = antibiotics resistance genes, ts = total samples, ps = positive samples, %P = percentage prevalence, SS = sample sources studied, algino = alginolyticus, para = parahaemolyticus, chol. = cholerae, AMR = antimicrobial resistance.
Note: All study considered were cross-sectional, experimental method = PCR, AMR breakpoint = CLSI.
The Prevalence and meta-analysis statistics of Vibrio species-ARG identified in the studied data.
| df | Sample | esp 95 % CI | Heterogeneity | esp | Variance | ||
|---|---|---|---|---|---|---|---|
| Q value | p value | I2 | |||||
| 9 | β-lactamase resistance genes | 27.93 (0.11–0.56) | 83.99 | 0.001 | 91.01 | 0.59 | 0.95 |
| 15 | quinolone, tetracycline and sulfonamide resistance genes | 32.97 (0.18–0.53) | 214.29 | 0.001 | 94.89 | 0.71 | 0.42 |
| 14 | Phenicol, macrolides and aminoglycoside resistance genes | 28.67 (0.15–0.47) | 151.45 | 0.001 | 93.36 | 0.91 | 0.41 |
df = degree of freedom; esp = estimate summary proportion/effect estimate; Q-statistic = Cochran's test; I2 = inverse variance index; es = Standard error.
Figure 2Prevalence of Vibrio species-ARG from the studied data.
Figure 3Countries distributions of Vibrio species-ARG from the studied data.
Figure 4Forest plots of the prevalence of β-lactamase resistance genes positive in Vibrio species isolate for random-effects model meta-analyses. (The confidence interval at 95% and random effect estimates of Vibrio species-ARG with size squares proportional to the weight assigned to the study in the meta-analysis).
Figure 5Forest plots of the prevalence of quinolone, tetracycline and sulfonamide resistance genes positive in Vibrio species isolates for random-effects model meta-analyses. (The confidence interval at 95% and random effect estimates of Vibrio species-ARG with size squares proportional to the weight assigned to the study in the meta-analysis).
Figure 6Forest plots of prevalence of phenicol, macrolides and aminoglycoside resistance genes positive in Vibrio species isolates for random-effects model meta-analyses. (The confidence interval at 95% and random effect estimates of Vibrio species-ARG with size squares proportional to the weight assigned to the study in the meta-analysis).
Figure 7Bias assessment is revealed by funnel plot of prevalence of β-lactamase resistance genes positive in Vibrio species isolates.
Figure 8Bias assessment is shown by funnel plot of prevalence of quinolone, tetracycline and sulfonamide resistance genes positive in Vibrio species isolates. The plot's diagonal line indicates 95 % confidence interval and the vertical line indicates the summary prevalence rate resulting from the random-effect model meta-analysis.
Figure 9Bias assessment is shown by funnel plot of prevalence of quinolone, tetracycline and sulfonamide resistance genes positive in Vibrio species isolates. The plot's diagonal line indicates 95 % confidence interval and the vertical line indicates the summary prevalence rate resulting from the random-effect model meta-analysis.
Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) Statement.
| Section/topic | # | Checklist item | Reported on page # |
|---|---|---|---|
| Title | 1 | Identify the report as a systematic review, meta-analysis, or both. | 1 |
| Structured summary | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 2 |
| Rationale | 3 | Describe the rationale for the review in the context of what is already known. | 3 - 6 |
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | 6 |
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. | No registration |
| Eligibility criteria | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | 7 |
| Information sources | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | 7-8 |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | A1 Text |
| Study selection | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | 7 |
| Data collection process | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | 6 - 8 |
| Data items | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | 6 -8 |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | 13 |
| Summary measures | 13 | State the principal summary measures (e.g., risk ratio, difference in means). | 13 |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. | 13 |
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). | 17, 19, 21 |
| Additional analyses | 16 | Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. | |
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. | 9, |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. | 10 – 12, Figures |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). | Figures |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. | Figures |
| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency. | Figures |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see Item 15). | Fig |
| Additional analysis | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). | Figure |
| Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). | 21-23 |
| Limitations | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). | 23 |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research. | 23 - 24 |
| Funding | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. | 24 |